Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Summary

• Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers.
• Multiple studies support the cost efficacy of Inpefa for heart failure, and this could become a more significant competitive differentiator for insurers if real-world experience follows accordingly.
• Lexicon also has other opportunities in its pipeline, including the development of LX9211 for diabetic peripheral neuropathic pain and a possible path to approval for sotagliflozin for Type 1 diabetes.
• Lexicon's track record is not the best, and while there is significant upside if Lexicon successfully commercializes Inpefa, failure is very much a possible outcome.

Mohammed Haneefa Nizamudeen

It's been an interesting few months for Lexicon Pharmaceuticals (NASDAQ:LXRX) since I last wrote about this small, commercialization-stage biotech. While the share price fell below $1 on a few occasions, increased optimism around the company's efforts to get

Analyst’s Disclosure: I/we have a beneficial long position in the shares of LXRX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.